Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps Latest publication
Casirivimab
Randomized controlled double-blind trial 		Emergency use authorization Experimental Antiviral Jan/23/2023
Imdevimab
Randomized controlled double-blind trial 		Emergency use authorization Experimental Antiviral Jan/23/2023
Remdesivir
Randomized controlled double-blind trial 		Approved by FDA Experimental Antiviral Jan/18/2023
Mesenchymal stem cells
Randomized controlled double-blind trial 		Potential treatment - clinical evidence Experimental Other treatment Oct/17/2022
Sotrovimab
Randomized controlled double-blind trial 		Emergency use authorization Experimental Antiviral Jul/14/2022
Nirmatrelvir
Randomized controlled double-blind trial 		Emergency use authorization Experimental Antiviral Jun/23/2022
Bamlanivimab
Randomized controlled double-blind trial 		Potential treatment - clinical evidence Experimental Antiviral Jun/23/2022
Etesevimab
Randomized controlled double-blind trial 		Potential treatment - clinical evidence Experimental Antiviral Jun/23/2022
Ad26.COV2.S
Randomized controlled double-blind trial 		Emergency use authorization Experimental Vaccine Jun/22/2022
BNT162b2
Randomized controlled double-blind trial 		Approved by FDA Experimental Vaccine Jun/22/2022
mRNA-1273
Randomized controlled double-blind trial 		Emergency use authorization Experimental Vaccine Jun/22/2022
Cilgavimab
Randomized controlled double-blind trial 		Emergency use authorization Experimental Antiviral Jun/18/2022
Tixagevimab
Randomized controlled double-blind trial 		Emergency use authorization Experimental Antiviral Jun/18/2022
REGEN-COV
Randomized controlled double-blind trial 		Emergency use authorization Experimental Antiviral Jun/03/2022
Convalescent plasma
Randomized controlled double-blind trial 		Emergency use authorization Experimental Antiviral May/16/2022
Anakinra 
Randomized controlled double-blind trial 		Recommended by guidelines Used to treat other disease Other treatment Apr/11/2022
Ivermectin
Randomized controlled double-blind trial 		Potential treatment - clinical evidence Used to treat other disease Antiviral Mar/30/2022
Baricitinib
Randomized controlled double-blind trial 		Emergency use authorization Used to treat other disease Other treatment Feb/03/2022
Colchicine
Randomized controlled double-blind trial 		Potential treatment - clinical evidence Used to treat other disease Other treatment Feb/02/2022
ChAdOx1 nCoV-19
Randomized controlled double-blind trial 		Emergency use authorization Experimental Vaccine Jan/04/2022
Export (.csv)